Theranos Overview
- Founded
- 2003

- Status
- Out of Business
- Employees
- 60

- Latest Deal Type
- Liquidation
Theranos General Information
Description
Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of diagnostic information.The company's proprietary miniLab created an integrated infrastructure for real-time testing, decision making and individualized therapy, enabling laboratories to process early detection and intervention.
Contact Information
- 1701 Page Mill Road
- Palo Alto, CA 94304
- United States
Theranos Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Bankruptcy: Liquidation | 05-Sep-2018 | 00000 | Completed | Out of Business | ||
9. Debt - General | 23-Dec-2017 | 00000 | 00000 | Completed | Generating Revenue/Not Profitable | |
8. Secondary Transaction - Private | 27-Mar-2017 | 00000 | Completed | Generating Revenue/Not Profitable | ||
7. Later Stage VC (Series C3) | 01-Oct-2015 | 00000 | 000.00 | Cancelled | Generating Revenue/Not Profitable | |
6. Later Stage VC (Series C2) | 04-Feb-2014 | 00000 | 00000 | 00.00 | Completed | Generating Revenue/Not Profitable |
5. Later Stage VC (Series C1) | 28-Mar-2013 | 0000 | 00000 | 00.000 | Completed | Generating Revenue/Not Profitable |
4. Later Stage VC (Series C1) | 08-Jul-2010 | 0000 | 000.00 | 00.000 | Completed | Generating Revenue/Not Profitable |
3. Later Stage VC (Series C) | 15-Nov-2006 | 000.00 | 000.00 | 00000 | Completed | Startup |
2. Early Stage VC (Series B) | 16-Feb-2006 | $9.1M | $16M | 0000 | Completed | Startup |
1. Early Stage VC (Series A) | 30-Mar-2005 | $6.95M | $6.95M | 000.00 | Completed | Startup |
Theranos Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C3 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
Series C2 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 | |
Series C1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series B | 54,162,965 | $0.000100 | $0.18 | $0.18 | 1x | $0.18 | 10.03% | |
Series A | 46,320,045 | $0.000100 | $0.15 | $0.15 | 1x | $0.15 | 8.58% |
Theranos Comparisons
Industry
00000000
00000 00
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialTheranos Competitors (6)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Everlywell | Venture Capital-Backed | Austin, TX | 00 | 00000 | 00000000000 | 00000 |
00000 0000000 | Venture Capital-Backed | Saint Paul, MN | 000 | 000.00 | 000000000 - | 000.00 |
000000 | Formerly VC-backed | Union City, CA | 000 | 000.00 | 000000&0 | 000.00 |
00000 00000000000 | Formerly VC-backed | Sydney, Australia | 00 | 000.00 | 00000000 | 000.00 |
00000000 000000 | Formerly VC-backed | York, United Kingdom | 00 | 000.00 | 00000000 | 000.00 |
Theranos Executive Team (18)
Theranos Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial